Organigram to Make Strategic Investment With Hyasynth Biologicals Inc.

Organigram Holdings Inc. (OGI) announced today that it has entered into a non-binding letter of intent with Hyasynth Biologicals Inc. Hyasynth is a biotechnology company that captured headlines several years ago with news that the company was capable of producing phytocannabinoids using genetically engineered strains of yeast; which allows the company to manufacture CBG, CBD, and THC for novel and specialized products, and as pharmaceutical ingredients.

Hyasynth was recently awarded by Health Canada a dealer’s license, which will allow Hyasynth to expand its operations beyond research and into commercial production

Under the LOI, Organigram will make a strategic investment in Hyasynth. The LOI also includes the possibility of Organigram entering into an off-take agreement with Hyasynth, in which Organigram could purchase a pre-defined quantity of a range of cannabinoids or cannabinoid-related production from Hyasynth.

Once the strategic investment is finalized, Organigram will have the right to purchase up to $10 million senior secured convertible debentures of Hyasynth, which would be completed in a series of three rounds. The second and third round would be contingent on Hyasynth attaining certain milestones.

Provided that Organigram engages in all three rounds the outstanding debt under the debentures would be converted into equity shares in Hyasynth which, if fully converted, would represent a considerable interest in the company. Additionally, Organigram will be granted certain investor rights and board representation.

“As a proven technology the use of bioreactors is an infinitely scalable process which should allow Hyasynth to produce pharmaceutical grade cannabinoids at a significantly lower cost than traditional plant-based production, which has numerous medical and adult recreational use applications,” said Organigram CEO, Greg Engel, in a statement. “The funding provided by Organigram will allow Hyasynth to refine and optimize its processes at scale via a contract manufacturer as well as fund a purpose-built manufacturing facility for production and also provides Organigram with the ability to purchase up to 25% of the cannabinoids produced by Hyasynth.”

William Sumner

William Sumner

William Sumner is a freelance writer specializing in the legal cannabis industry. You can follow William on Twitter @W_Sumner or on Medium.


Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 19 hours

Please help support Go visit our Patreon page

@GreenMarketRpt – 20 hours

$HARV.CN $HTHHF Harvest Forms $100 Million Joint Venture For Real Estate Projects

@GreenMarketRpt – 21 hours

$HEXO $HYYDF ⁦@Hexocorp⁩ Hexo Reports C$5.2 Million For Just Two Weeks Of Adult Use Cannabis Sales #earnings…

Back to Top

You have Successfully Subscribed!